SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i’s promote a general shift to fasting state metabolism characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Adingupu, Damilola D., Göpel, Sven O., Grönros, Julia, Behrendt, Margareta, Sotak, Matus, Miliotis, Tasso, Dahlqvist, Ulrika, Gan, Li-Ming, Jönsson-Rylander, Ann-Cathrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366096/
https://www.ncbi.nlm.nih.gov/pubmed/30732594
http://dx.doi.org/10.1186/s12933-019-0820-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366096/
https://www.ncbi.nlm.nih.gov/pubmed/30732594
http://dx.doi.org/10.1186/s12933-019-0820-6

Ejemplares similares